Titan Medical to Report Year End 2021 Financial Results on March 24, 2022
March 14 2022 - 7:30AM
Business Wire
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical
technology company focused on single access robotic-assisted
surgery (RAS), today announced that the company plans to issue its
year end 2021 financial results prior to market opening on
Thursday, March 24, 2022. In addition, management will host an
investor audio webcast at 8:30 a.m. ET to discuss financial results
and business highlights. Speakers will include Paul Cataford,
Interim President and Chief Executive Officer, and Stephen Lemieux,
Chief Financial Officer.
A link to the live audio webcast will be made available on the
"Investor Relations" section of the Company’s website,
www.titanmedicalinc.com. A webcast replay will be archived and
accessible on the Company’s website shortly after conclusion of the
live audio webcast.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company headquartered in Toronto, Ontario and with operations in
Chapel Hill, North Carolina, is focused on enhancing robotic
assisted surgery using innovative technology through a single
access point. The Enos™ robotic single access surgical system is
being developed with an ergonomic focus to provide a surgical
experience that imitates real-life movements that surgeons demand
and includes multi-articulating instruments designed to allow
surgeons an increased range of motion in a confined space, with
dexterity and the ability to exert the forces necessary to complete
common surgical tasks. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com and follow
@TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
company’s future growth, results of operations, performance and
business prospects and opportunities. Forward-looking statements
are frequently, but not always, identified by words such as “may”,
“would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions, although these words may not be present in all
forward-looking statements. Forward-looking statements that appear
in this release may include, without limitation, references to: the
company’s focus on the design and development of surgical
technologies for robotic single access surgery; the Enos system
providing a surgical experience that imitates real-life movements;
and the company’s intention to initially pursue gynecologic
surgical indications with the Enos system. These statements reflect
management’s current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the company’s Annual Information Form and Form 40-F for the fiscal
year ended December 31, 2020 (which may be viewed at www.sedar.com
and at www.sec.gov). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions, the company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements. Except as required by law, the company expressly
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220314005196/en/
Kristen Galfetti Vice President Investor Relations &
Corporate Communications +1-781-869-2553
investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2023 to Apr 2024